Member Info for Thompi

Bantham, I don’t get the compulsion to come back on a board after you have sold. Say what you have to and then move on. I think it might have been Dave, on ADVFN , who said if he sold he didnt post anymore, it was bad manners. I have paraphrased, but the sentiment is the same.

I have sold shares at a loss, POLX most recently. I haven’t looked at the SP since and I would only comment on it if I came across some research that I thought would be genuinely useful. It didn’t turn out how I hoped, but I have accepted that and left. Why feel the need to come back on the AGL board?

I did have a wry smile to myself when CF mentioned in the Q&A that he gets some criticism for “maybe over-hype.” I wonder why CF 🤔. But fair play to him he hasn’t sold any of POLB or Hvivo, and said he would like to buy more POLB when he has an opportunity and is “free of inside information”.

Thanks Wally, your notes are exceptional. JS talks very, very fast, there is no way I could keep up with taking notes. That is an excellent summary, thank you.

BV & Matml, your reading of it makes more sense than mine. I think I interpreted the wording wrongly.

Matml74, I think you may need to quote the full context of the TG note. I took it to mean that the Royal Marsden could potentially provide patients for further indications?

“Though sarcomas are a relatively rare cancer, if we get AVA6000 registered in this indication you can then broaden out into other indications such as breast and ovarian. With Bill Tap’s help in the US and the Royal Marsden we can ensure sufficient clinical trial patients. A successful P2 is critical.” (TG notes)

Hi Tim - “*I think* he stated phase 2 will be US only (could have imagined that).”

I think you are correct. It was mentioned by AS during the interims, approx 21:07 into the presentation. But listening to it again, I could have misinterpreted it?

AS said:

“So that phase 2 study will be in soft tissue sarcoma, we'll release more information on which subtypes and more detail on that phase 2 study when we can. But it'll be a study in Soft Tissue Sarcoma, and it will be designed to be a registrational study in the US.”

https://youtu.be/LKoI83jSpDM?si=7fOxHBYDPO9QLOT1

Not only do we have William Tap’s invaluable experience in navigating the complexities of the FDA, but Eliot Forster is also well versed with the processes (plus, of course, licensing and deal making).

Someone (I’m sorry I can’t remember who it was) posted a podcast featuring Eliot Forster. He has lived and worked in the US. During his time out there with Pfizer he went through three successful FDA submissions.

In the podcast he talks about “really getting a sense in particular of the FDA, we went through three submissions during that period we were out there, successfully fortunately, and got a flavour for the importance of US markets/regulations. And, indeed how Pharma is done there, which is kind of the same and different just because of scale in particular, but also processes.”

https://www.buzzsprout.com/1992308/13248337

I agree PL75 that it’s baseless “concern” the FUD about Neil Bell. And as Soleboy pointed out, he can hardly have dominated Science Day because he wasn’t there. AS briefly commented on his absence in the beginning of his Strategic Overview (about 5:33 into the presentation) - “I would like to just say Neil Bell unfortunately can't be with us today because of a personal issue so he would obviously otherwise be with us but can't be”. If I had to look for an inference from that comment, then I would assume ill health.

Incidentally NB is still showing as a member of the Therapeutics team and is still on LinkedIn: July 2020 - Present.

https://avacta.com/therapeutics/therapeutics-team/

Hi WeAreGroot, “Didn’t the TG notes also mention AS saying he hoped they would publish case studies with the data?”

Yes, your recollection is correct. This is from the TG notes:

“…….we intend to present the full pharmacokinetic data and clinical data later in Q4 including case studies if that is permitted……

We’ve had a patient in the P1a trial who has had a significant reduction in tumour volume which continues to shrink, this will be a great news story, and once all the phase 1 data is fully validated we will use that to communicate the huge potential of pre|CISION and Avacta. The press want stories about cures for cancer, safety trials are less interesting. A few months ago we had no hints of efficacy and did not expect to have them. We are now able to talk about safer chemo with dramatically reduced side effects and some hints of efficacy so we are starting to engage more with mainstream media.”

Another example today of how a potential deal could possibly be structured. There is so much “optionality” now for AVCT.

A collaboration between AZ & Cellectis. Upfront payment for Cellectis ($25m), equity investment by AZ in Cellectis ($80M) option fees/milestone payments, tiered royalties….

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-signs-drug-development-deal-with-biotech-cellectis-2023-11-01/

Not “traumatised” by you NY. But you would get the Rotten Tomatoes award for the worst script. Unless you meant it to be funny? In that case it was hilarious 🤣

We get good posts and then it sometimes just degenerates into embarrassing vitriol. Sometimes it can be amusing and other times it’s just excruciatingly bad. Today was one of those days. “We broke you then and we'll do it again”, seriously, that is just dreadful.

Is there anyone, please, with a greater medical/scientific knowledge than myself (mine is virtually zero) help me understand a point raised in the TG meeting notes.

I understand the definition of what a drugs “half-life” means - “Drugs with a longer half-life may take longer to start working, but their effects persist for longer, and they may only need to be dosed once a day, once a week, once a month, or even less frequently”.

The question asked at the meeting was-

“TG: How long before AVA6000 is cleared, what is the half-life? What is the FAP concentration?

FM: AVA6000 is eliminated in about 4 to 6 hours. Dox by comparison doesn’t hang around long. Dox has a short initial plasma half-life. When dosed Dox goes to the patients’ tissues very quickly. The maximum blood concentration is reached quickly and then there is a long terminal half-life.

A number of doxorubicin metabolites as well as the leaving group are measured. Because they are small they are measured in the urine.

Concentration of FAP is one thing but what’s important to pre|CISION is the ‘Activity’ of the enzyme because it has to be active to release doxorubicin. The presence of FAP alone does not mean there is activity.”

What is the significance (if any?) of the difference between the half-life times of Dox & AVA6000?

Could I have a pint 🍺 of whatever Indy is drinking and I agree with what he says.

Icecool, I understand the scepticism but the notes are genuine. There was never going to be any sensitive information revealed, but it was important that the notes were vetted due to concern that other parties (TW etc) would create mischief. Albert has tried to put the issue to bed on Twitter. I’m not really sure there is much more he can say.

https://x.com/albertmay59/status/1717643833482133823?s=61&t=yGNoQ6Xj0Lw6rjPJMTuiZA

“Ive heard a rumour. AS is going to invite a select group of LSE posters to a Xmas knees up at the Weatherby Whaler.”

That made me smile RD. I have this image of the TG group being all refined and then us (not so select) lot turning up at the Wetherby Whaler Xmas knees up like a gang from the Bash Street Kids. Unruly, unkempt and wearing badges with “Twat” on as our proof of membership 😀

Yuyus, you are wrong. The TG meeting definitely happened. It perhaps got more attention than it would have done because Ophidian made a sly dig about it in a tweet because he wasn’t invited. But it did happen.

Credit to the Telegram group & Albert for organising and coordinating a meeting with AS. Collectively they hold a significant amount of shares.

I’m no big fan of Oph because of all the people he has had chucked off on there, but I understand he has left the group now.

Wonder if the uber rampers of two weeks ago get a twinge of embarrassment when one of their rampy predictions don’t materialise.

https://x.com/ophidian18/status/1712119518330310886?s=61&t=yGNoQ6Xj0Lw6rjPJMTuiZA

“Broker Cavendish maintained its target price of 19p, which is almost triple

POLB's current share price.”